Merck KGaA (ETR:MRK)

Germany flag Germany · Delayed Price · Currency is EUR
114.25
+1.20 (1.06%)
Jul 29, 2025, 10:19 AM CET
1.06%
Market Cap49.15B
Revenue (ttm)21.32B
Net Income (ttm)2.82B
Shares Out434.78M
EPS (ttm)6.48
PE Ratio17.45
Forward PE12.94
Dividend2.20 (1.95%)
Ex-Dividend DateApr 28, 2025
Volume21,873
Average Volume363,109
Open113.25
Previous Close113.05
Day's Range113.25 - 114.40
52-Week Range103.00 - 177.00
Beta0.64
RSI55.90
Earnings DateAug 7, 2025

About Merck KGaA

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]

Sector Healthcare
Founded 1668
Employees 59,020
Stock Exchange Deutsche Börse Xetra
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.

Financial Statements

News

Merck Foundation Together with African and Asian First Ladies Mark ‘World Assisted Reproductive Technology Day’ 2025 Through Their ‘More Than a Mother’ Campaign

Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ‘World ART (Assisted Reproductive Technology) Day 2025′ together with African and Asian First Ladies, who are also the Ambassadors ...

3 days ago - Business Upturn

MilliporeSigma and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration

Strengthens 90-year legacy of partnership between MilliporeSigma and WashU to accelerate scientific progress Strategic academic-industry alliance aims to build robust Research & Development talent pip...

4 days ago - Financial Post

Merck KGaA gets EU nod for Ezmekly

10 days ago - Seeking Alpha

European Commission Grants Conditional Approval of EZMEKLY (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – STAMFORD,...

10 days ago - Wallstreet:Online

Europe is lagging behind in AI-specific patents: Merck KGaA

Kai Beckmann, CEO of Electronics at Merck KGaA, discusses Europe's competitiveness in AI development.

12 days ago - CNBC

MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation

New platform powered by Opentrons expands lab automation to accelerate scientific discovery Plug-and-play design for effortless integration into diverse laboratory settings Validated protocols across ...

13 days ago - Financial Post

EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 07.07.2...

21 days ago - Wallstreet:Online

Dr. Rasha Kelej Meets Mauritius President to Strengthen Partnership to Improve Access to Innovative and Equitable Healthcare and Empower Women in STEM

Senator, Dr. Rasha Kelej, CEO of Merck Foundation, the philanthropic arm of Merck KGaA Germany met HIS EXCELLENCY MR. DHARAMBEER GOKHOOL, The President of Republic of Mauritius, during a high-level me...

24 days ago - Business Upturn

Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for...

27 days ago - Business Wire

Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai

Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 on 19th and 20th June in Dubai, United Arab Emi...

5 weeks ago - Business Upturn

MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant

Winner’s lead therapy targets Parkinson’s disease; platform addresses 6,000+ genetic disorders Neoclease gains access to MilliporeSigma’s technologies and expert support to scale its AI-designed gene-...

5 weeks ago - Financial Post

EQS-PVR: Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of ...

6 weeks ago - Wallstreet:Online

China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China...

7 weeks ago - Benzinga

China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical P...

7 weeks ago - Business Wire

China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (N...

7 weeks ago - Business Wire

EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 05.06.2...

7 weeks ago - Wallstreet:Online

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX...

7 weeks ago - Wallstreet:Online

Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor

Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo (p<0.00...

2 months ago - Benzinga

Merck Foundation Chairman and CEO Meet Nigeria First Lady to Underscore Their Long-Term Commitment to Transform Patient Care Landscape in the Country

Abuja, Nigeria & Mumbai, Maharashtra, India: Merck Foundation, the philanthropic arm of Merck KGaA Germany underscored their commitment to build healthcare capacity, support girl education and break i...

2 months ago - Business Upturn

EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement in disease activity at Week 16 Enpato...

2 months ago - Benzinga

Merck KGaA Cuts Outlook Amid Macroeconomic Challenges

The German life-sciences and electronics company slashed its full-year guidance on the back of challenging macroeconomic conditions and foreign-exchange headwinds.

2 months ago - WSJ